AKT1 and cancer: Inhibition of the PI3K/Akt/mTOR signaling pathway has a promising clinical efficacy since activation of autophagy by the PI3K/Akt/mTOR inhibitors can enhance treatment sensitivity and trigger cell survival once drug resistance occurs in cancer cells.37